researchers are gaining a more detailed understanding of why immunotherapies, while prosperous against some cancers, often struggle too eliminate solid tumors. A team at the University of Pennsylvania has pioneered a “tumor-on-a-chip” model-a microengineered system containing human cells and blood vessels-to observe the complex interactions between cancer cells and the immune system [[1]]. This innovation, coupled with the surprising discovery of an existing diabetes drug’s potential anti-cancer properties, may accelerate the development of more effective treatments for the vast majority of cancer patients diagnosed with solid tumors.
Researchers at the University of Pennsylvania have developed a novel “tumor-on-a-chip” model that allows them to observe how cancer cells evade the body’s immune response. This innovative tool offers a new pathway for developing more effective treatments for solid tumors, the most common type of cancer, and represents a significant step forward in understanding why some immunotherapies fail.
Why Immunotherapy Struggles with Solid Tumors
Table of Contents
Immunotherapies, such as CAR-T-cell therapy, have shown remarkable success in treating blood cancers. However, their effectiveness is significantly reduced when it comes to solid tumors like lung or breast cancer. This is largely due to the tumor microenvironment (TME), a protective ecosystem surrounding the cancer cells that shields them from immune system attacks.
Understanding the intricacies of this complex environment is crucial for improving existing immunotherapies and designing new ones that can overcome these defenses.
A Miniature Tumor in the Lab
To investigate this process, the University of Pennsylvania team created a miniaturized version of a human tumor within a transparent chip. This “tumor-on-a-chip” contains real human cells and microscopic blood vessels, enabling scientists to meticulously track how immune cells navigate the tumor and interact with cancer cells. The model provides a realistic platform to study why immune cells sometimes fail to eliminate tumors and what strategies can be employed to enhance their attack.
Existing Diabetes Drug Offers New Insights
The research revealed that cells lining the blood vessels of a tumor emit short chemical signals that guide immune cells to the tumor site. However, these signals degrade quickly, causing immune cells to lose their direction once the signals disappear.
Researchers found that administering vildagliptin – a medication already approved for the treatment of type 2 diabetes – prevented the rapid breakdown of these crucial chemical signals. As a result, a greater number of immune cells were able to reach and attack the tumor. This finding suggests a potential new use for an existing medication in cancer treatment.
Key Enzyme Identified
Through a comprehensive analysis of genetic, protein, and metabolic data, the team identified the enzyme DPP4 as responsible for breaking down the signaling molecules. Because DPP4 inhibitors, like vildagliptin, are already known to be safe for human use, this opens the possibility of repurposing the drug for cancer therapies.
Faster Testing, Reduced Animal Research
The tumor-on-a-chip technology allows researchers to test new therapies without relying on animal models. This approach can more accurately predict how human cells will respond to treatment before clinical trials begin, potentially accelerating the development of effective cancer therapies.
This development represents a significant advancement toward more effective, safer, and personalized immunotherapies. The research combines bio-engineering, data science, and precision medicine, demonstrating the power of technology to accelerate cancer research.
The results were published in the scientific journal Nature Biotechnology.
Source: Nature Biotechnology, University of Pennsylvania
